IL-15 Agonist Impresses in Non-Muscle Invasive Bladder Cancer
CHICAGO — Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) had a high response rate and 2-year cancer-specific survival with an immunostimulatory fusion protein complex plus BCG, a prospective study showed. The intravesical combination led to complete responses in 71% of patients with carcinoma in situ (CIS), with a median response duration exceeding 2 years. […]